NovaBiotics is a global leading, privately held clinical stage biotechnology company. To date, the business has raised over £25 million in equity funding and £3.5 million in non-dilutive grant funding.
The Company’s portfolio and robust and risk-diversified pipeline comprises immune derived compounds that have been derived from NovaBiotics’ proprietary peptide platform (NP213, NP339 and NP432) and aminothiol platform (NM001 and NM002).
NovaBiotics’ experienced board and management team remain focused on high-value opportunities and the delivery of commercial success from the Company’s solid technology base.
The Company has a strong, wholly-owned IP portfolio with multiple patent families granted and pending, protecting NovaBiotics’ technology worldwide.
To find out more about investment opportunities, contact us.